-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.O2.6 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Upcoming Therapies in Newly Diagnosed and Relapsed/Refractory AML

Symposia: Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Acute Myeloid Malignancies, AML, Clinical Research, Diseases, Myeloid Malignancies
Saturday, December 9, 2023: 9:30 AM-11:00 AM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
Lindsay Wilde, MD, Sidney Kimmel Cancer Center, Jefferson Health and Andrew H. Wei, MBBS, PhD, Peter MacCallum Cancer Centre and Royal Melbourne Hospital
Disclosures:
Wilde: Gilead: Research Funding; Protagonist: Research Funding.
This session includes novel therapies that have potential to change practice, 2 studies with selinexor (one in peds), 2 menin inhibitor studies, 1 anti-CD47 and 1 anti TIM3.
9:30 AM

Li Yang1*, Fangli Chen1*, Hong Liang2*, Yunsong Bai3*, Wenzhong Wu4*, Xiaojing Yan5*, Jinhai Ren, MD6*, Si Li2*, Yang Yu2*, Laigen Tong4*, Deng Pan, MD, PhD5* and Ligen Liu, MD1

1Department of Hematology , Hongqiao International institute of Medicine ,Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2Department of Hematology & Oncology,Harbin Institute of Hematology & Oncology, haerbin, China
3Department of Hematology, China-japan union hospital of jilin university, changchun, China
4Yixing People's Hospital, yixing, China
5The First Hospital of China Medical University, Shenyang, China
6Department of Hematology, The second hospital of Hebei medical university, Shijiazhuang, CHN

9:45 AM

Sara Zarnegar-Lumley, MD1, Seth E. Karol, MD2, Stanley Pounds, PhD3*, Jeffery M. Klco, MD, PhD4, Maria Luisa Sulis, MD5, Dennis John Kuo, MD, MS6*, Kenneth Matthew Heym, MD7*, Kathleen Ludwig, MD8*, Alexandra McLean Stevens9*, Thomas B. Alexander, MD, MPH10, Kelly Elizabeth Faulk, MD11, Himalee S. Sabnis, MD, MS12*, Sarah K Tasian, MD13, Jeffrey Taub, MD14, Andrew E. Place, MD, PhD15 and Jeffrey E. Rubnitz, MD, PhD16

1Department of Pediatrics, Division of Hematology/Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
2Department of Oncology, St Jude Children's Research Hospital, Memphis, TN
3Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
4St. Jude Children's Research Hospital, Memphis, TN
5Memorial Sloan Kettering Cancer Center, New York, NY
6Rady Children's Hospital, University of California San Diego, San Diego, CA
7Department of Pediatrics, Cook Children's Medical Center, Fort Worth, TX
8University of Texas Southwestern, Dallas, TX
9Texas Children's Hospital Baylor College of Medicine, Houston, TX
10Department of Pediatrics, Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC
11Children's Hospital Colorado, Aurora, CO
12Children's Healthcare of Atlanta, Atlanta, GA
13Children's Hospital of Philadelphia, Philadelphia, PA
14Children's Hosp. of Michigan, Detroit, MI
15Division of Pediatric Hematology/Oncology, Boston Children’s Hospital, Boston, MA
16Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

10:00 AM

Elias Jabbour1, Emma Searle2*, Maher Abdul-Hay, M.D.3*, Sameem Abedin, MD4, Ibrahim Aldoss, MD5, Ana Alfonso Piérola, MD, PhD6*, Juan Manuel Alonso-Dominguez, MD, PhD7*, Patrice Chevallier, MD8, Carrye Cost, MD9*, Nikki Daskalakis, MD9*, Richard Dillon, PhD, MRCP, FRCPath10*, Neil Dunavin, MD, MS11*, Jordi Esteve, MD, PhD12, Amir T. Fathi, MD13, Pasquale L. Fedele, MBBS, PhD, FRACP, FRCPA14*, Lucille Ferrante, MD, MS9, Sylvain Garciaz15*, Christina Guttke, PhD9*, Emmanuel Gyan16,17,18, Brett Hiebert, MS19*, Min Chul Kwon20, Jonathan Miller, MD, PhD21*, Teng Fong Ng, BSc, MBBS, MRCP, FRACP, FRCPA22*, Kathryn Packman, PhD23*, Ulrike Philippar, PhD20, Arnaud Pigneux, MD, PhD24*, Christian Recher, MD, PhD25*, Olga Salamero, MD26*, Madhu Sanga, PhD27*, Richard M Stone, MD28, Peter Tan, MBBS (Hons), Mphil, FRACP, FRCPA29*, Jan Willem Thuring, PhD20*, Trevor Tucker9* and Paresh Vyas, FMedSci, DPhil, FRCPath30*

1Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX
2The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom
3Blood and Marrow Transplantation and Cellular Therapy, Laura and Issac Perlmutter Cancer Center at NYU Langone Health, New York, NY
4Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
5City of Hope National Medical Center, Duarte, CA
6Clínica Universidad de Navarra, Pamplona, Spain
7Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
8CHU de Nantes - Hôtel Dieu, Nantes, France
9Janssen Research & Development, LLC, Spring House, PA
10Guy’s Hospital and King’s College, London, United Kingdom
11University of California San Francisco, San Francisco, CA
12Hematology Department, Hospital Clínic Barcelona, Barcelona, Spain
13Massachusetts General Hospital, Harvard Medical School, Boston, MA
14Haematology Department, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia
15Hematology Department, Integrative Structural and Chemical Biology, Aix-Marseille Université, Inserm, CNRS, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Marseille, France
16CHU de Tours, Service d'Hématologie & Thérapie Cellulaire, Centre Hospitalier Universitaire, Tours, France
17Equipe CNRS ERL9001 Leukemic Niche and RedOx Metabolism, Université de Tours, Tours, France
18Centre d'Investigation Clinique INSERM U1415, Centre Hospitalier Universitaire, Tours, France
19IQVIA, Winnipeg, MB, Canada
20Janssen Research & Development, LLC, Beerse, Belgium
21Janssen Research & Development, LLC, Raritan, NJ
22Gold Coast University Hospital, Southport, QLD, Australia
23Janssen Research & Development, LLC, Cambridge, MA
24Centre Hospitalier Universitaire de Bordeaux, Hôpital Haut Lévêque - Centre François Magendie, Pessac, France
25CHU de Toulouse, Institut Universitaire du Cancer Toulouse – Oncopole, Toulouse, France
26Department of Hematology and Experimental Hematology, Vall d’Hebron Institute of Oncology, University Hospital Vall d’Hebron, Barcelona, Spain
27Janssen Research & Development, LLC, Brisbane, CA
28Dana-Farber Cancer Institute, Boston, MA
29Royal Perth Hospital, Perth, Australia
30MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

10:15 AM

Ghayas C. Issa1, Branko Cuglievan2, Courtney D. DiNardo, MD, MSc1, Nicholas J. Short, MD1, David McCall, MD3*, Amber Gibson, DO4*, Cesar Nunez, MD4*, Miriam B. Garcia, DO4*, Michael Roth, MD5, Aram Bidikian, MD1*, Allison Pike, RN1*, Sheila Tan, RN1*, Brianna Kammerer, BSN, MS, RN5*, Musa Yilmaz, MD1*, Tapan M. Kadia, MD1, Naveen Pemmaraju, MD1, Maro Ohanian, DO1*, Naval Daver, MD1, Elias Jabbour6, Gautam Borthakur, MD1, Farhad Ravandi, MD, MBBS1, Guillermo Garcia-Manero, MD7, Michael Andreeff, MD PhD1 and Hagop M. Kantarjian, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2The University of Texas MD Anderson Cancer Center, Houston, TX
3Division of Pediatrics, MD Anderson, Houston, TX
4Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX
6University of Texas M.D. Anderson Cancer Ctr., Houston, TX
7University of Texas MD Anderson Cancer Center, Houston, TX

10:30 AM

Robert Zeiser, MD1, Raynier Devillier, MD, PhD2*, Maria Caterina Mico'3*, David Valcarcel4*, Simon Call, MD5*, Christian Niederwieser, MD6*, Claire Nourry, PhD7*, Yunnan Xu, PhD8*, Thierry Medts, PhD7*, Nathalie Guichard7*, Hans D. Menssen, MD, PhD7 and Nicola Polverelli, MD9

1Department of Medicine I, Medical Center University of Freiburg, Freiburg, Germany
2Hematology and Transplantation, Institut Paoli-Calmettes, Aix Marseille University, Marseille, France
3Department of Hematology and Bone Marrow Transplant, ASST Papa Giovanni XXIII, Bergamo, Italy
4Department of Hematology, University Hospital Vall d’Hebron, Barcelona, Spain
5Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
6Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Novartis Pharma AG, Basel, Switzerland
8Novartis Pharmaceuticals Corporation, East Hanover, NJ
9Unit of Blood Diseases and Bone Marrow Transplantation, Department of Clinical and Experimental Sciences, University of Brescia, ASST Spedali Civili di Brescia, Brescia, Italy

10:45 AM

Yuchen Liu, MD1, Dominique Bollino1*, Osman M Bah, MPH1*, Erin T Strovel, PhD2*, Jinoos Zarrabi, BS1*, Sunita Philip, MBBS, MPH1*, Ezzat Mostafa, MBChB1*, Rena G Lapidus, PhD2*, Maria R. Baer, MD3, Sandrine Niyongere, MD1, Vu H. Duong, MD, MS3, Christine C Dougherty, CRNP, MSN, OCN1*, Katherine Caprinolo, BSN, RN1* and Ashkan Emadi, MD, PhD1

1University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
2University of Maryland School of Medicine, Baltimore, MD
3Department of Medicine, University of Maryland School of Medicine, Baltimore, MD

*signifies non-member of ASH